Novartis study offers new evidence of Ultibro Breezhaler’s COPD benefits

Novartis has announced the findings of a new clinical trial demonstrating the benefits its drug Ultibro Breezhaler offers for chronic obstructive pulmonary disease (COPD) patients.

The FLASH study has examined the safety and efficacy of directly switching COPD patients from an established steroid-containing therapy to Ultibro Breezhaler, revealing that those who switched experienced significantly improved lung function.

This marks the first randomised controlled trial to confirm the benefits of directly switching patients from steroid therapies to Novartis' dual bronchodilator, allowing patients to avoid the side effects of the long-term use of inhaled corticosteroids.

It was also shown that the safety and tolerability profiles of the two treatments were similar. Previous clinical studies have shown that Ultibro Breezhaler improves patients' lung function when directly compared to steroid therapies.

Shreeram Aradhye, chief medical officer and global head of medical affairs for Novartis Pharmaceuticals, said: "The FLASH study provides further evidence that it is possible to reduce the burden of long-term inhaled steroids in many COPD patients, as recommended by global treatment guidelines."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.